StockMacro
Company, fund or insider

Help

Menu

4D Molecular Therapeutics

$10.23 +17% in 6 monthsMarket cap $576.8M

FDMT on XNAS, Health Care, 4D Molecular Therapeutics, Inc., job postings

Measures activity, not value. Not investment advice.

Revenue jumped to $96.1M, but the net loss hit $200.4M and shares fell 19% in a month.

  • GoodInstitutional holders rose to 167 from 158 the quarter before

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
196
Website
4dmoleculartherapeutics.com
Listed
Nasdaq, US
Last results
12 Nov 2026
Next results
expected around 6 Jan 2027 (an estimate: a year ago it reported on 7 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $4.1M, net loss $78.1M.
Quarter to 31 Dec 2021: revenue –, net income -$25.1MQuarter to 31 Mar 2022: revenue $1.2M, net income -$26.3MQuarter to 31 Mar 2022: revenue $1.2M, net income -$26.3MQuarter to 30 Jun 2022: revenue $162K, net income -$28.1MQuarter to 30 Jun 2022: revenue $162K, net income -$28.1MQuarter to 30 Sep 2022: revenue $500K, net income -$25.7MQuarter to 30 Sep 2022: revenue $500K, net income -$25.7MQuarter to 31 Dec 2022: revenue $1.2M, net income -$27.4MQuarter to 31 Dec 2022: revenue $1.2M, net income -$27.4MQuarter to 31 Mar 2023: revenue $298K, net income -$28.7MQuarter to 31 Mar 2023: revenue $298K, net income -$28.7MQuarter to 30 Jun 2023: revenue $239K, net income -$29.6MQuarter to 30 Jun 2023: revenue $239K, net income -$29.6MQuarter to 30 Sep 2023: revenue $20.2M, net income -$10.3MQuarter to 30 Sep 2023: revenue $20.2M, net income -$10.3MQuarter to 31 Dec 2023: revenue –, net income -$32.3MQuarter to 31 Mar 2024: revenue $28K, net income -$32.4MQuarter to 31 Mar 2024: revenue $28K, net income -$32.4MQuarter to 30 Jun 2024: revenue $5K, net income -$35.0MQuarter to 30 Jun 2024: revenue $5K, net income -$35.0MQuarter to 30 Sep 2024: revenue $3K, net income -$43.8MQuarter to 30 Sep 2024: revenue $3K, net income -$43.8MQuarter to 31 Dec 2024: revenue $1K, net income -$49.7MQuarter to 31 Dec 2024: revenue $1K, net income -$49.7MQuarter to 31 Mar 2025: revenue $14K, net income -$48.0MQuarter to 31 Mar 2025: revenue $14K, net income -$48.0MQuarter to 30 Jun 2025: revenue $15K, net income -$54.7MQuarter to 30 Jun 2025: revenue $15K, net income -$54.7MQuarter to 30 Sep 2025: revenue $90K, net income -$56.9MQuarter to 30 Sep 2025: revenue $90K, net income -$56.9MQuarter to 31 Dec 2025: revenue $85.1M, net income $19.4MQuarter to 31 Dec 2025: revenue $85.1M, net income $19.4MQuarter to 31 Mar 2026: revenue $3.0M, net income -$68.8MQuarter to 31 Mar 2026: revenue $3.0M, net income -$68.8MQuarter to 30 Jun 2026: revenue $3.8M, net income -$72.9MQuarter to 30 Jun 2026: revenue $3.8M, net income -$72.9MQuarter to 30 Sep 2026: revenue $4.1M, net income -$78.1MQuarter to 30 Sep 2026: revenue $4.1M, net income -$78.1M
31 Dec 2021RevenueNet incomeNet losstallest bar $85.1M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$4.1M-$78.1M
30 Jun 2026$3.8M-$72.9M
31 Mar 2026$3.0M-$68.8M
31 Dec 2025$85.1M$19.4M
30 Sep 2025$90K-$56.9M
30 Jun 2025$15K-$54.7M
31 Mar 2025$14K-$48.0M
31 Dec 2024$1K-$49.7M
30 Sep 2024$3K-$43.8M
30 Jun 2024$5K-$35.0M
31 Mar 2024$28K-$32.4M
31 Dec 2023–-$32.3M
30 Sep 2023$20.2M-$10.3M
30 Jun 2023$239K-$29.6M
31 Mar 2023$298K-$28.7M
31 Dec 2022$1.2M-$27.4M
30 Sep 2022$500K-$25.7M
30 Jun 2022$162K-$28.1M
31 Mar 2022$1.2M-$26.3M
31 Dec 2021–-$25.1M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $96.1M $120K
Revenue growthRevenue of the last 12 months compared with the 12 months before. +79952% +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$200.4M -$209.2M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$2.70 -$3.75
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -226% – -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -209% – -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -56.7% -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $307.0M $305.1M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $19.7M $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$287.3M (net cash) -$305.1M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.06 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. –
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. 6.0 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 3.0 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 1.7 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
4D Molecular TherapeuticsFDMT (this company) $576.8Mloss6.0+79952%-209%
Cullinan TherapeuticsCGEM $577.1Mloss–––
Entera BioENTX $575.5Mloss–––
Surrozen, Inc. CommonSRZN $542.5Mloss51.5+192%–
Iambic TherapeuticsIAM $621.4M––––
Electra TherapeuticsETRA $509.8M––––

Insider buy/sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$1.6M

bought $0, sold $1.6M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+5.7%

167 13F filers vs 158

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

–

No 13F holdings or share count.

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

–

10.9M shares sold short (30 Oct 2026); no share count in the company's filings in our data

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

10.4

10.9M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-5.5%

11.5M shares sold short in the report before, 10.9M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

53%

53% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 58%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

19

Tracked since 20 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 20 Nov 2026; the change shows after 30 days.

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

18

18 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

18×

18 articles in the last 7 days; its usual week has 1.

Price $10.23 on 20 Nov 2026, -1.1% over 12 months (12-month range $7.19 to $16.76)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders sold a net $5.3M in the last 12 months (the 12 months before: -$109K).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 0 published in the last 12 months, -100% on the 12 months before.
Revenue per quarter. Revenue $4.1M in the latest quarter, +4506% on a year earlier.
Capital spending per quarter. Capital spending $49K in the latest quarter.
Institutional holders (13F filers). 167 13F filers reported holding it in the latest 13F quarter, +35% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
16 Jun 2026Sharp changeShort interest spike: short interest spike, 12.2M vs usual 5.0M (2026-05-29); 2.8x the same period a year earlier
2 Jun 2026Sharp changeShort interest spike: short interest spike, 12.1M vs usual 4.9M (2026-05-15); 2.6x the same period a year earlier
12 May 2026Sharp changeShort interest spike: short interest spike, 12.0M vs usual 4.9M (2026-04-30); 2.4x the same period a year earlier
28 Apr 2026Sharp changeShort interest spike: short interest spike, 11.5M vs usual 4.9M (2026-04-15); 2.2x the same period a year earlier
14 Apr 2026Sharp changeShort interest spike: short interest spike, 10.9M vs usual 4.9M (2026-03-31); 2.1x the same period a year earlier
31 Mar 2026Sharp changeShort interest spike: short interest spike, 10.4M vs usual 4.9M (2026-03-13); 2.1x the same period a year earlier
30 Mar 20268-K and other filingsDirector or officer change
19 Mar 2026Sharp changeQuarterly revenue change: quarterly revenue change, 85.1M vs usual 9,500 (2025-12-31); 85090.0x the same period a year earlier
17 Mar 2026Sharp changeShort interest spike: short interest spike, 10.1M vs usual 4.9M (2026-02-27); 1.9x the same period a year earlier
3 Mar 2026Sharp changeShort interest spike: short interest spike, 9.7M vs usual 4.9M (2026-02-13); 1.6x the same period a year earlier
17 Feb 2026Sharp changeShort interest spike: short interest spike, 9.3M vs usual 4.9M (2026-01-30); 1.3x the same period a year earlier
3 Feb 2026Sharp changeShort interest spike: short interest spike, 9.5M vs usual 4.9M (2026-01-15); 1.2x the same period a year earlier
13 Jan 2026Sharp changeShort interest spike: short interest spike, 8.7M vs usual 4.9M (2025-12-31); 1.1x the same period a year earlier
7 Jan 20268-K and other filingsDirector or officer change
17 Nov 20258-K and other filingsDirector or officer change
2 Oct 20258-K and other filingsDirector or officer change
2 Oct 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
2 Jul 20258-K and other filingsDirector or officer change
2 Jul 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
13 Aug 2024Sharp changeShort interest spike: short interest spike, 9.5M vs usual 4.0M (2024-07-31); 3.1x the same period a year earlier
30 Jul 2024Sharp changeShort interest spike: short interest spike, 10.3M vs usual 3.9M (2024-07-15); 3.3x the same period a year earlier
16 Jul 2024Sharp changeShort interest spike: short interest spike, 9.9M vs usual 3.9M (2024-06-28); 2.8x the same period a year earlier
2 Jul 2024Sharp changeShort interest spike: short interest spike, 9.7M vs usual 3.8M (2024-06-14); 2.8x the same period a year earlier
18 Jun 2024Sharp changeShort interest spike: short interest spike, 9.6M vs usual 3.7M (2024-05-31); 3.1x the same period a year earlier
28 May 2024Sharp changeShort interest spike: short interest spike, 9.6M vs usual 3.6M (2024-05-15); 3.3x the same period a year earlier
21 May 2024Sharp changeMany funds opening a new position: many funds opening a new position, 51 vs usual 17.50 (2024-03-31); 3.9x the same period a year earlier
14 May 2024Sharp changeShort interest spike: short interest spike, 9.6M vs usual 3.6M (2024-04-30); 3.4x the same period a year earlier
30 Apr 2024Sharp changeShort interest spike: short interest spike, 9.8M vs usual 3.6M (2024-04-15); 3.1x the same period a year earlier
16 Apr 2024Sharp changeShort interest spike: short interest spike, 9.3M vs usual 3.5M (2024-03-28); 3.0x the same period a year earlier
2 Apr 2024Sharp changeShort interest spike: short interest spike, 8.5M vs usual 3.5M (2024-03-15); 3.3x the same period a year earlier
12 Mar 2024Sharp changeShort interest spike: short interest spike, 8.3M vs usual 3.5M (2024-02-29); 4.0x the same period a year earlier
5 Mar 2024Sharp changeShort interest spike: short interest spike, 7.1M vs usual 3.3M (2024-02-15); 3.2x the same period a year earlier
4 Jan 20248-K and other filingsDirector or officer change
4 Jan 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Nov 2023Sharp changeQuarterly revenue change: quarterly revenue change, 20.2M vs usual 860K (2023-09-30); 40.4x the same period a year earlier
13 Sep 20238-K and other filingsDirector or officer change
13 Sep 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
29 Nov 2022Sharp changeShort interest spike: short interest spike, 2.7M vs usual 1.7M (2022-11-15); 2.3x the same period a year earlier
15 Nov 2022Sharp changeShort interest spike: short interest spike, 2.9M vs usual 1.6M (2022-10-31); 1.8x the same period a year earlier
1 Nov 2022Sharp changeShort interest spike: short interest spike, 2.9M vs usual 1.6M (2022-10-14); 1.8x the same period a year earlier
27 Sep 20228-K and other filingsDirector or officer change
27 Sep 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
17 May 2022Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 6.4M vs usual 721K (2022-03-31); 10.0x the same period a year earlier
29 Mar 2022Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 5.1M vs usual 682K (2021-12-31); 10.0x the same period a year earlier
22 Feb 20228-K and other filingsDirector or officer change
22 Feb 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Dec 2022: -$2.2M published
Month from 1 Jan 2023: -$392K published
Month from 1 Feb 2023: -$710K published
Month from 1 Mar 2023: -$43K published
Month from 1 Apr 2023: -$175K published
Month from 1 May 2023: $13.6M published
Month from 1 Jun 2023: -$119K published
Month from 1 Jan 2024: -$12.6M published
Month from 1 Feb 2024: -$3.5M published
Month from 1 Mar 2024: -$316K published
Month from 1 Apr 2024: -$304K published
Month from 1 May 2024: -$45K published
Month from 1 Jun 2024: -$340K published
Month from 1 Jul 2024: -$479K published
Month from 1 Aug 2024: -$8K published
Month from 1 Sep 2024: -$8K published
Month from 1 Sep 2025: -$19K published
Month from 1 Oct 2025: -$73K published
Month from 1 Nov 2025: -$17K published
Month from 1 Dec 2025: -$21K published
Month from 1 Mar 2026: -$3K published
Month from 1 Jun 2026: -$1.3M published
Month from 1 Jul 2026: -$830K published
Month from 1 Aug 2026: -$1.5M published
Month from 1 Sep 2026: -$841K published
Month from 1 Oct 2026: -$775K published
H-1B/E-3 applications certified
Quarter from 1 Oct 2022: 1 published
Quarter from 1 Jan 2023: 1 published
Quarter from 1 Apr 2024: 2 published
Quarter from 1 Jul 2024: 1 published
Quarter from 1 Jul 2025: 1 published
Revenue per quarter
Quarter ended 31 Mar 2022: $1.2M, -39% on a year earlier; public on 13 May 2022
Quarter ended 30 Jun 2022: $162K, -99% on a year earlier; public on 12 Aug 2022
Quarter ended 30 Sep 2022: $500K, -63% on a year earlier; public on 9 Nov 2022
Quarter ended 31 Dec 2022: $1.2M; public on 16 Mar 2023
Quarter ended 31 Mar 2023: $298K, -76% on a year earlier; public on 12 May 2023
Quarter ended 30 Jun 2023: $239K, +48% on a year earlier; public on 10 Aug 2023
Quarter ended 30 Sep 2023: $20.2M, +3941% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Mar 2024: $28K, -91% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $5K, -98% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $3K, -100% on a year earlier; public on 14 Nov 2024
Quarter ended 31 Dec 2024: $1K; public on 1 Mar 2025
Quarter ended 31 Mar 2025: $14K, -50% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $15K, +200% on a year earlier; public on 12 Aug 2025
Quarter ended 30 Sep 2025: $90K, +2900% on a year earlier; public on 11 Nov 2025
Quarter ended 31 Dec 2025: $85.1M, +8508900% on a year earlier; public on 19 Mar 2026
Quarter ended 31 Mar 2026: $3.0M, +21664% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $3.8M, +25107% on a year earlier; public on 14 Aug 2026
Quarter ended 30 Sep 2026: $4.1M, +4506% on a year earlier; public on 13 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $5.1M, +903% on a year earlier; public on 29 Mar 2022
Quarter ended 31 Mar 2022: $6.4M, +899% on a year earlier; public on 13 May 2022
Quarter ended 30 Jun 2022: $2.1M, +180% on a year earlier; public on 12 Aug 2022
Quarter ended 30 Sep 2022: $2.0M, -25% on a year earlier; public on 9 Nov 2022
Quarter ended 31 Dec 2022: $1.1M, -79% on a year earlier; public on 16 Mar 2023
Quarter ended 31 Mar 2023: $1.0M, -84% on a year earlier; public on 12 May 2023
Quarter ended 30 Jun 2023: $805K, -61% on a year earlier; public on 10 Aug 2023
Quarter ended 30 Sep 2023: $405K, -79% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Dec 2023: $549K, -50% on a year earlier; public on 1 Mar 2024
Quarter ended 31 Mar 2024: $710K, -30% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $349K, -57% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $1.8M, +339% on a year earlier; public on 14 Nov 2024
Quarter ended 31 Dec 2024: $949K, +73% on a year earlier; public on 1 Mar 2025
Quarter ended 30 Jun 2025: $66K, -81% on a year earlier; public on 12 Aug 2025
Quarter ended 30 Sep 2026: $49K; public on 13 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 72; public on 14 Feb 2022
31 Mar 2022 report: 78; public on 16 May 2022
30 Jun 2022 report: 88; public on 15 Aug 2022
30 Sep 2022 report: 84; public on 14 Nov 2022
31 Dec 2022 report: 90; public on 14 Feb 2023
31 Mar 2023 report: 92; public on 15 May 2023
30 Jun 2023 report: 96; public on 14 Aug 2023
30 Sep 2023 report: 104; public on 14 Nov 2023
31 Dec 2023 report: 103; public on 14 Feb 2024
31 Mar 2024 report: 143; public on 15 May 2024
30 Jun 2024 report: 135; public on 14 Aug 2024
30 Sep 2024 report: 132; public on 14 Nov 2024
31 Dec 2024 report: 142; public on 14 Feb 2025
31 Mar 2025 report: 120; public on 15 May 2025
30 Jun 2025 report: 114; public on 14 Aug 2025
30 Sep 2025 report: 124; public on 14 Nov 2025
31 Dec 2025 report: 147; public on 17 Feb 2026
31 Mar 2026 report: 148; public on 15 May 2026
30 Jun 2026 report: 158; public on 14 Aug 2026
30 Sep 2026 report: 167; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is revenue, quarter at $4.1M (30 Sep 2026), 79× its normal quarter; higher than 83% of its own history.
  • Short interest spike: had 12.1M shares sold short in the 15 May 2026 report, 2.6× the same report last year Public on 28 May 2026.
  • Insider net buying (open market): Insiders sold a net $5.3M in the last 12 months (the 12 months before: -$109K).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 0 published in the last 12 months, -100% on the 12 months before.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 60 insider trades

Last 90 days: 5 sales, $1.6M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
20 Oct 2026Scott BizilyChief Legal OfficerSellplanned in advance (10b5-1); after exercising options1,635$12.84$21KForm 4
7 Oct 2026David KirnSee RemarksSellplanned in advance (10b5-1)58,333$12.92$754KForm 4
22 Sep 2026Scott BizilyChief Legal OfficerSellplanned in advance (10b5-1); after exercising options1,635$13.65$22KForm 4
16 Sep 2026David KirnSee RemarksSellplanned in advance (10b5-1)58,333$13.90$811KForm 4
3 Sep 2026Scott BizilyChief Legal OfficerSellplanned in advance (10b5-1); after exercising options584$14.00$8KForm 4
21 Aug 2026David KirnSee RemarksSellplanned in advance (10b5-1); after exercising options69,076$15.76$1.1MForm 4
17 Aug 2026Scott BizilyChief Legal OfficerSellplanned in advance (10b5-1); after exercising options3,270$12.10$40KForm 4
5 Aug 2026David KirnSee RemarksSellplanned in advance (10b5-1)26,842$10.23$275KForm 4

167 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 27 opened a position, 17 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Janus Henderson Group Ltd.5.7M11.5%$81.9M
Ra Capital Management, L.P.5.0M10.1%$72.3MNo change
BlackRock, Inc.4.7M9.49%$67.6M+179K+3.9%
Goldman Sachs Group Inc3.9M7.90%$56.2M-328K-7.7%
Novo Holdings A/S3.0M6.03%$42.9M-249K-7.7%
BVF Inc2.9M5.78%$41.2MNo change
State Street Corp2.5M4.96%$35.3M-442K-15%
Adage Capital Partners GP, L.L.C.2.3M4.60%$32.8M+40K+1.8%
T. Rowe Price Investment Management, Inc.2.3M4.55%-246K-9.8%
Trails Edge Capital Partners, LP2.2M4.48%$31.9MNo change

Company events

All 21 company events

In 12 months: 2 director or officer changes, 1 major agreement. Results releases and routine reports are left out.

FiledWhat happenedSource
29 Jun 2026Signed a major agreementSame filing: took on new debt8-K
30 Mar 2026Director or officer change8-K
7 Jan 2026Director or officer change8-K
17 Nov 2025Director or officer change8-K
31 Oct 2025Signed a major agreement8-K
2 Oct 2025Director or officer changeSame filing: changed its bylaws or fiscal year8-K
2 Jul 2025Director or officer change8-K
7 Jun 2024Signed a major agreement8-K

19 open postings; careers site tracked since 20 Nov 2026. Most in Finance & accounting 21%, Legal, policy & compliance 21%, Operations & administration 16%, Corporate IT 11%.

PostedJobLocation
20 Nov 2026Clinical Research Associate (Contract)Research & scienceEmeryville, California
18 Nov 2026Administrative Assistant (Contract)Executive & administrative supportEmeryville, California
17 Nov 2026Senior Accountant (Contract)Finance & accountingEmeryville, California
14 Nov 2026Senior Accountant (R&D)Finance & accountingEmeryville, California
10 Nov 2026TMF Quality Specialist (Contract)Test, quality & reliabilityEmeryville, California
9 Nov 2026AD, Clinical Operations (Contract)Operations & administrationRemote, United States
9 Nov 2026Senior Clinical Trial Manager (Contract)Operations & administrationRemote, United States
6 Nov 2026Sr. R&D IT ManagerCorporate ITEmeryville, California

The 5 newest of 109 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

19 Mar 2026confirmed

Confirmed across sources Filings + Financials and Short interest and volume

4D Molecular Therapeutics (FDMT): reported revenue of $85.1M for the quarter ended 31 Dec 2025, 85,090× the same quarter last year, while it had 12.0M shares sold short in the 30 Apr 2026 report, 2.4× the same report last year. Two unrelated kinds of activity within 119 days.

  • Short interest and volume: Short interest spike, became public on 11 Feb 2026
  • Short interest and volume: Short interest spike, became public on 26 Feb 2026
  • Short interest and volume: Short interest spike, became public on 11 Mar 2026
  • Financials: Quarterly revenue change, became public on 19 Mar 2026
  • Short interest and volume: Short interest spike, became public on 25 Mar 2026
  • Short interest and volume: Short interest spike, became public on 11 Apr 2026
  • Short interest and volume: Short interest spike, became public on 25 Apr 2026
  • Short interest and volume: Short interest spike, became public on 12 May 2026
  • Short interest and volume: Short interest spike, became public on 28 May 2026
  • Short interest and volume: Short interest spike, became public on 10 Jun 2026
2023-12-31: $02024-03-31: $28K2024-06-30: $5K2024-09-30: $3K2024-12-31: $1K2025-03-31: $14K2025-06-30: $15K2025-09-30: $90K2025-12-31: $85.1M
The quarter ended 31 Dec 2025 against the 8 quarters before it. this quarterearliernormal: $10K
See the evidence (10 changes)

Short interest and volume: Short interest spike became public on 11 Feb 2026

4D Molecular Therapeutics had 9.3M shares sold short in the 30 Jan 2026 report, 1.3× the same report last year.

This period
9.3M (the 30 Jan 2026 report)
Normal report (median of 24 earlier)
4.9M
Typical spread (median absolute deviation)
534K
How far from its usual level
+5.6
Same report last year
7.4M
History used
1,872 days
2025-01-31: 7.4M2025-02-14: 6.2M2025-02-28: 5.2M2025-03-14: 5.0M2025-03-31: 5.1M2025-04-15: 5.2M2025-04-30: 5.0M2025-05-15: 4.7M2025-05-30: 4.4M2025-06-13: 4.2M2025-06-30: 3.9M2025-07-15: 3.6M2025-07-31: 3.7M2025-08-15: 4.1M2025-08-29: 4.3M2025-09-15: 4.7M2025-09-30: 4.5M2025-10-15: 4.2M2025-10-31: 4.3M2025-11-14: 5.2M2025-11-28: 5.0M2025-12-15: 5.0M2025-12-31: 8.7M2026-01-15: 9.5M2026-01-30: 9.3M
the 30 Jan 2026 report24 earlier reportsnormal: 4.9M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 26 Feb 2026

4D Molecular Therapeutics had 9.7M shares sold short in the 13 Feb 2026 report, 1.6× the same report last year.

This period
9.7M (the 13 Feb 2026 report)
Normal report (median of 24 earlier)
4.9M
Typical spread (median absolute deviation)
534K
How far from its usual level
+6.1
Same report last year
6.2M
History used
1,886 days
2025-02-14: 6.2M2025-02-28: 5.2M2025-03-14: 5.0M2025-03-31: 5.1M2025-04-15: 5.2M2025-04-30: 5.0M2025-05-15: 4.7M2025-05-30: 4.4M2025-06-13: 4.2M2025-06-30: 3.9M2025-07-15: 3.6M2025-07-31: 3.7M2025-08-15: 4.1M2025-08-29: 4.3M2025-09-15: 4.7M2025-09-30: 4.5M2025-10-15: 4.2M2025-10-31: 4.3M2025-11-14: 5.2M2025-11-28: 5.0M2025-12-15: 5.0M2025-12-31: 8.7M2026-01-15: 9.5M2026-01-30: 9.3M2026-02-13: 9.7M
the 13 Feb 2026 report24 earlier reportsnormal: 4.9M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 11 Mar 2026

4D Molecular Therapeutics had 10.1M shares sold short in the 27 Feb 2026 report, 1.9× the same report last year.

This period
10.1M (the 27 Feb 2026 report)
Normal report (median of 24 earlier)
4.9M
Typical spread (median absolute deviation)
534K
How far from its usual level
+6.7
Same report last year
5.2M
History used
1,900 days
2025-02-28: 5.2M2025-03-14: 5.0M2025-03-31: 5.1M2025-04-15: 5.2M2025-04-30: 5.0M2025-05-15: 4.7M2025-05-30: 4.4M2025-06-13: 4.2M2025-06-30: 3.9M2025-07-15: 3.6M2025-07-31: 3.7M2025-08-15: 4.1M2025-08-29: 4.3M2025-09-15: 4.7M2025-09-30: 4.5M2025-10-15: 4.2M2025-10-31: 4.3M2025-11-14: 5.2M2025-11-28: 5.0M2025-12-15: 5.0M2025-12-31: 8.7M2026-01-15: 9.5M2026-01-30: 9.3M2026-02-13: 9.7M2026-02-27: 10.1M
the 27 Feb 2026 report24 earlier reportsnormal: 4.9M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Financials: Quarterly revenue change became public on 19 Mar 2026

4D Molecular Therapeutics reported revenue of $85.1M for the quarter ended 31 Dec 2025, 85,090× the same quarter last year.

This period
$85.1M (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
$10K
Typical spread (median absolute deviation)
$8K
How far from its usual level
+85.1
Same quarter last year
$1K
History used
2,101 days
2023-12-31: $02024-03-31: $28K2024-06-30: $5K2024-09-30: $3K2024-12-31: $1K2025-03-31: $14K2025-06-30: $15K2025-09-30: $90K2025-12-31: $85.1M
the quarter ended 31 Dec 20258 earlier quartersnormal: $10K

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Short interest and volume: Short interest spike became public on 25 Mar 2026

4D Molecular Therapeutics had 10.4M shares sold short in the 13 Mar 2026 report, 2.1× the same report last year.

This period
10.4M (the 13 Mar 2026 report)
Normal report (median of 24 earlier)
4.9M
Typical spread (median absolute deviation)
574K
How far from its usual level
+6.5
Same report last year
5.0M
History used
1,914 days
2025-03-14: 5.0M2025-03-31: 5.1M2025-04-15: 5.2M2025-04-30: 5.0M2025-05-15: 4.7M2025-05-30: 4.4M2025-06-13: 4.2M2025-06-30: 3.9M2025-07-15: 3.6M2025-07-31: 3.7M2025-08-15: 4.1M2025-08-29: 4.3M2025-09-15: 4.7M2025-09-30: 4.5M2025-10-15: 4.2M2025-10-31: 4.3M2025-11-14: 5.2M2025-11-28: 5.0M2025-12-15: 5.0M2025-12-31: 8.7M2026-01-15: 9.5M2026-01-30: 9.3M2026-02-13: 9.7M2026-02-27: 10.1M2026-03-13: 10.4M
the 13 Mar 2026 report24 earlier reportsnormal: 4.9M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 11 Apr 2026

4D Molecular Therapeutics had 10.9M shares sold short in the 31 Mar 2026 report, 2.1× the same report last year.

This period
10.9M (the 31 Mar 2026 report)
Normal report (median of 24 earlier)
4.9M
Typical spread (median absolute deviation)
612K
How far from its usual level
+6.6
Same report last year
5.1M
History used
1,932 days
2025-03-31: 5.1M2025-04-15: 5.2M2025-04-30: 5.0M2025-05-15: 4.7M2025-05-30: 4.4M2025-06-13: 4.2M2025-06-30: 3.9M2025-07-15: 3.6M2025-07-31: 3.7M2025-08-15: 4.1M2025-08-29: 4.3M2025-09-15: 4.7M2025-09-30: 4.5M2025-10-15: 4.2M2025-10-31: 4.3M2025-11-14: 5.2M2025-11-28: 5.0M2025-12-15: 5.0M2025-12-31: 8.7M2026-01-15: 9.5M2026-01-30: 9.3M2026-02-13: 9.7M2026-02-27: 10.1M2026-03-13: 10.4M2026-03-31: 10.9M
the 31 Mar 2026 report24 earlier reportsnormal: 4.9M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Apr 2026

4D Molecular Therapeutics had 11.5M shares sold short in the 15 Apr 2026 report, 2.2× the same report last year.

This period
11.5M (the 15 Apr 2026 report)
Normal report (median of 24 earlier)
4.9M
Typical spread (median absolute deviation)
662K
How far from its usual level
+6.8
Same report last year
5.2M
History used
1,947 days
2025-04-15: 5.2M2025-04-30: 5.0M2025-05-15: 4.7M2025-05-30: 4.4M2025-06-13: 4.2M2025-06-30: 3.9M2025-07-15: 3.6M2025-07-31: 3.7M2025-08-15: 4.1M2025-08-29: 4.3M2025-09-15: 4.7M2025-09-30: 4.5M2025-10-15: 4.2M2025-10-31: 4.3M2025-11-14: 5.2M2025-11-28: 5.0M2025-12-15: 5.0M2025-12-31: 8.7M2026-01-15: 9.5M2026-01-30: 9.3M2026-02-13: 9.7M2026-02-27: 10.1M2026-03-13: 10.4M2026-03-31: 10.9M2026-04-15: 11.5M
the 15 Apr 2026 report24 earlier reportsnormal: 4.9M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 12 May 2026

4D Molecular Therapeutics had 12.0M shares sold short in the 30 Apr 2026 report, 2.4× the same report last year.

This period
12.0M (the 30 Apr 2026 report)
Normal report (median of 24 earlier)
4.9M
Typical spread (median absolute deviation)
701K
How far from its usual level
+6.9
Same report last year
5.0M
History used
1,962 days
2025-04-30: 5.0M2025-05-15: 4.7M2025-05-30: 4.4M2025-06-13: 4.2M2025-06-30: 3.9M2025-07-15: 3.6M2025-07-31: 3.7M2025-08-15: 4.1M2025-08-29: 4.3M2025-09-15: 4.7M2025-09-30: 4.5M2025-10-15: 4.2M2025-10-31: 4.3M2025-11-14: 5.2M2025-11-28: 5.0M2025-12-15: 5.0M2025-12-31: 8.7M2026-01-15: 9.5M2026-01-30: 9.3M2026-02-13: 9.7M2026-02-27: 10.1M2026-03-13: 10.4M2026-03-31: 10.9M2026-04-15: 11.5M2026-04-30: 12.0M
the 30 Apr 2026 report24 earlier reportsnormal: 4.9M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 28 May 2026

4D Molecular Therapeutics had 12.1M shares sold short in the 15 May 2026 report, 2.6× the same report last year.

This period
12.1M (the 15 May 2026 report)
Normal report (median of 24 earlier)
4.9M
Typical spread (median absolute deviation)
844K
How far from its usual level
+5.8
Same report last year
4.7M
History used
1,977 days
2025-05-15: 4.7M2025-05-30: 4.4M2025-06-13: 4.2M2025-06-30: 3.9M2025-07-15: 3.6M2025-07-31: 3.7M2025-08-15: 4.1M2025-08-29: 4.3M2025-09-15: 4.7M2025-09-30: 4.5M2025-10-15: 4.2M2025-10-31: 4.3M2025-11-14: 5.2M2025-11-28: 5.0M2025-12-15: 5.0M2025-12-31: 8.7M2026-01-15: 9.5M2026-01-30: 9.3M2026-02-13: 9.7M2026-02-27: 10.1M2026-03-13: 10.4M2026-03-31: 10.9M2026-04-15: 11.5M2026-04-30: 12.0M2026-05-15: 12.1M
the 15 May 2026 report24 earlier reportsnormal: 4.9M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 Jun 2026

4D Molecular Therapeutics had 12.2M shares sold short in the 29 May 2026 report, 2.8× the same report last year.

This period
12.2M (the 29 May 2026 report)
Normal report (median of 24 earlier)
5.0M
Typical spread (median absolute deviation)
1.2M
How far from its usual level
+3.9
Same report last year
4.4M
History used
1,991 days
2025-05-30: 4.4M2025-06-13: 4.2M2025-06-30: 3.9M2025-07-15: 3.6M2025-07-31: 3.7M2025-08-15: 4.1M2025-08-29: 4.3M2025-09-15: 4.7M2025-09-30: 4.5M2025-10-15: 4.2M2025-10-31: 4.3M2025-11-14: 5.2M2025-11-28: 5.0M2025-12-15: 5.0M2025-12-31: 8.7M2026-01-15: 9.5M2026-01-30: 9.3M2026-02-13: 9.7M2026-02-27: 10.1M2026-03-13: 10.4M2026-03-31: 10.9M2026-04-15: 11.5M2026-04-30: 12.0M2026-05-15: 12.1M2026-05-29: 12.2M
the 29 May 2026 report24 earlier reportsnormal: 5.0M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

21 May 2024confirmed

Confirmed across sources Institutional holdings and Short interest and volume

4D Molecular Therapeutics (FDMT): saw 51 13F filers open a new position in the quarter ended 31 Mar 2024, 3.9× the same quarter last year, while it had 9.7M shares sold short in the 14 Jun 2024 report, 2.8× the same report last year. Two unrelated kinds of activity within 105 days.

  • Short interest and volume: Short interest spike, became public on 25 Apr 2024
  • Short interest and volume: Short interest spike, became public on 10 May 2024
  • Institutional holdings: Many funds opening a new position, became public on 15 May 2024
  • Short interest and volume: Short interest spike, became public on 25 May 2024
  • Short interest and volume: Short interest spike, became public on 12 Jun 2024
  • Short interest and volume: Short interest spike, became public on 27 Jun 2024
  • Short interest and volume: Short interest spike, became public on 11 Jul 2024
  • Short interest and volume: Short interest spike, became public on 25 Jul 2024
  • Short interest and volume: Short interest spike, became public on 10 Aug 2024
2022-03-31: 82022-06-30: 232022-09-30: 122022-12-31: 232023-03-31: 132023-06-30: 202023-09-30: 182023-12-31: 172024-03-31: 51
The quarter ended 31 Mar 2024 against the 8 quarters before it. this quarterearliernormal: 17.5
See the evidence (9 changes)

Short interest and volume: Short interest spike became public on 25 Apr 2024

4D Molecular Therapeutics had 9.8M shares sold short in the 15 Apr 2024 report, 3.1× the same report last year.

This period
9.8M (the 15 Apr 2024 report)
Normal report (median of 24 earlier)
3.6M
Typical spread (median absolute deviation)
385K
How far from its usual level
+11.0
Same report last year
3.2M
History used
1,217 days
2023-04-14: 3.2M2023-04-28: 2.8M2023-05-15: 3.0M2023-05-31: 3.1M2023-06-15: 3.4M2023-06-30: 3.5M2023-07-14: 3.1M2023-07-31: 3.1M2023-08-15: 3.6M2023-08-31: 3.6M2023-09-15: 3.7M2023-09-29: 3.9M2023-10-13: 4.1M2023-10-31: 3.5M2023-11-15: 3.8M2023-11-30: 3.6M2023-12-15: 3.9M2023-12-29: 3.2M2024-01-12: 2.9M2024-01-31: 3.8M2024-02-15: 7.1M2024-02-29: 8.3M2024-03-15: 8.5M2024-03-28: 9.3M2024-04-15: 9.8M
the 15 Apr 2024 report24 earlier reportsnormal: 3.6M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 May 2024

4D Molecular Therapeutics had 9.6M shares sold short in the 30 Apr 2024 report, 3.4× the same report last year.

This period
9.6M (the 30 Apr 2024 report)
Normal report (median of 24 earlier)
3.6M
Typical spread (median absolute deviation)
418K
How far from its usual level
+9.7
Same report last year
2.8M
History used
1,232 days
2023-04-28: 2.8M2023-05-15: 3.0M2023-05-31: 3.1M2023-06-15: 3.4M2023-06-30: 3.5M2023-07-14: 3.1M2023-07-31: 3.1M2023-08-15: 3.6M2023-08-31: 3.6M2023-09-15: 3.7M2023-09-29: 3.9M2023-10-13: 4.1M2023-10-31: 3.5M2023-11-15: 3.8M2023-11-30: 3.6M2023-12-15: 3.9M2023-12-29: 3.2M2024-01-12: 2.9M2024-01-31: 3.8M2024-02-15: 7.1M2024-02-29: 8.3M2024-03-15: 8.5M2024-03-28: 9.3M2024-04-15: 9.8M2024-04-30: 9.6M
the 30 Apr 2024 report24 earlier reportsnormal: 3.6M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Institutional holdings: Many funds opening a new position became public on 15 May 2024

4D Molecular Therapeutics saw 51 13F filers open a new position in the quarter ended 31 Mar 2024, 3.9× the same quarter last year.

This period
51 (the quarter ended 31 Mar 2024)
Normal quarter (median of 8 earlier)
17.5
Typical spread (median absolute deviation)
5
How far from its usual level
+4.5
Same quarter last year
13
History used
1,186 days
2022-03-31: 82022-06-30: 232022-09-30: 122022-12-31: 232023-03-31: 132023-06-30: 202023-09-30: 182023-12-31: 172024-03-31: 51
the quarter ended 31 Mar 20248 earlier quartersnormal: 17.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Short interest and volume: Short interest spike became public on 25 May 2024

4D Molecular Therapeutics had 9.6M shares sold short in the 15 May 2024 report, 3.3× the same report last year.

This period
9.6M (the 15 May 2024 report)
Normal report (median of 24 earlier)
3.6M
Typical spread (median absolute deviation)
440K
How far from its usual level
+9.2
Same report last year
3.0M
History used
1,247 days
2023-05-15: 3.0M2023-05-31: 3.1M2023-06-15: 3.4M2023-06-30: 3.5M2023-07-14: 3.1M2023-07-31: 3.1M2023-08-15: 3.6M2023-08-31: 3.6M2023-09-15: 3.7M2023-09-29: 3.9M2023-10-13: 4.1M2023-10-31: 3.5M2023-11-15: 3.8M2023-11-30: 3.6M2023-12-15: 3.9M2023-12-29: 3.2M2024-01-12: 2.9M2024-01-31: 3.8M2024-02-15: 7.1M2024-02-29: 8.3M2024-03-15: 8.5M2024-03-28: 9.3M2024-04-15: 9.8M2024-04-30: 9.6M2024-05-15: 9.6M
the 15 May 2024 report24 earlier reportsnormal: 3.6M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 12 Jun 2024

4D Molecular Therapeutics had 9.6M shares sold short in the 31 May 2024 report, 3.1× the same report last year.

This period
9.6M (the 31 May 2024 report)
Normal report (median of 24 earlier)
3.7M
Typical spread (median absolute deviation)
440K
How far from its usual level
+9.0
Same report last year
3.1M
History used
1,263 days
2023-05-31: 3.1M2023-06-15: 3.4M2023-06-30: 3.5M2023-07-14: 3.1M2023-07-31: 3.1M2023-08-15: 3.6M2023-08-31: 3.6M2023-09-15: 3.7M2023-09-29: 3.9M2023-10-13: 4.1M2023-10-31: 3.5M2023-11-15: 3.8M2023-11-30: 3.6M2023-12-15: 3.9M2023-12-29: 3.2M2024-01-12: 2.9M2024-01-31: 3.8M2024-02-15: 7.1M2024-02-29: 8.3M2024-03-15: 8.5M2024-03-28: 9.3M2024-04-15: 9.8M2024-04-30: 9.6M2024-05-15: 9.6M2024-05-31: 9.6M
the 31 May 2024 report24 earlier reportsnormal: 3.7M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 27 Jun 2024

4D Molecular Therapeutics had 9.7M shares sold short in the 14 Jun 2024 report, 2.8× the same report last year.

This period
9.7M (the 14 Jun 2024 report)
Normal report (median of 24 earlier)
3.8M
Typical spread (median absolute deviation)
482K
How far from its usual level
+8.3
Same report last year
3.4M
History used
1,277 days
2023-06-15: 3.4M2023-06-30: 3.5M2023-07-14: 3.1M2023-07-31: 3.1M2023-08-15: 3.6M2023-08-31: 3.6M2023-09-15: 3.7M2023-09-29: 3.9M2023-10-13: 4.1M2023-10-31: 3.5M2023-11-15: 3.8M2023-11-30: 3.6M2023-12-15: 3.9M2023-12-29: 3.2M2024-01-12: 2.9M2024-01-31: 3.8M2024-02-15: 7.1M2024-02-29: 8.3M2024-03-15: 8.5M2024-03-28: 9.3M2024-04-15: 9.8M2024-04-30: 9.6M2024-05-15: 9.6M2024-05-31: 9.6M2024-06-14: 9.7M
the 14 Jun 2024 report24 earlier reportsnormal: 3.8M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 11 Jul 2024

4D Molecular Therapeutics had 9.9M shares sold short in the 28 Jun 2024 report, 2.8× the same report last year.

This period
9.9M (the 28 Jun 2024 report)
Normal report (median of 24 earlier)
3.9M
Typical spread (median absolute deviation)
718K
How far from its usual level
+5.6
Same report last year
3.5M
History used
1,291 days
2023-06-30: 3.5M2023-07-14: 3.1M2023-07-31: 3.1M2023-08-15: 3.6M2023-08-31: 3.6M2023-09-15: 3.7M2023-09-29: 3.9M2023-10-13: 4.1M2023-10-31: 3.5M2023-11-15: 3.8M2023-11-30: 3.6M2023-12-15: 3.9M2023-12-29: 3.2M2024-01-12: 2.9M2024-01-31: 3.8M2024-02-15: 7.1M2024-02-29: 8.3M2024-03-15: 8.5M2024-03-28: 9.3M2024-04-15: 9.8M2024-04-30: 9.6M2024-05-15: 9.6M2024-05-31: 9.6M2024-06-14: 9.7M2024-06-28: 9.9M
the 28 Jun 2024 report24 earlier reportsnormal: 3.9M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Jul 2024

4D Molecular Therapeutics had 10.3M shares sold short in the 15 Jul 2024 report, 3.3× the same report last year.

This period
10.3M (the 15 Jul 2024 report)
Normal report (median of 24 earlier)
3.9M
Typical spread (median absolute deviation)
836K
How far from its usual level
+5.2
Same report last year
3.1M
History used
1,308 days
2023-07-14: 3.1M2023-07-31: 3.1M2023-08-15: 3.6M2023-08-31: 3.6M2023-09-15: 3.7M2023-09-29: 3.9M2023-10-13: 4.1M2023-10-31: 3.5M2023-11-15: 3.8M2023-11-30: 3.6M2023-12-15: 3.9M2023-12-29: 3.2M2024-01-12: 2.9M2024-01-31: 3.8M2024-02-15: 7.1M2024-02-29: 8.3M2024-03-15: 8.5M2024-03-28: 9.3M2024-04-15: 9.8M2024-04-30: 9.6M2024-05-15: 9.6M2024-05-31: 9.6M2024-06-14: 9.7M2024-06-28: 9.9M2024-07-15: 10.3M
the 15 Jul 2024 report24 earlier reportsnormal: 3.9M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 Aug 2024

4D Molecular Therapeutics had 9.5M shares sold short in the 31 Jul 2024 report, 3.1× the same report last year.

This period
9.5M (the 31 Jul 2024 report)
Normal report (median of 24 earlier)
4.0M
Typical spread (median absolute deviation)
1.0M
How far from its usual level
+3.6
Same report last year
3.1M
History used
1,324 days
2023-07-31: 3.1M2023-08-15: 3.6M2023-08-31: 3.6M2023-09-15: 3.7M2023-09-29: 3.9M2023-10-13: 4.1M2023-10-31: 3.5M2023-11-15: 3.8M2023-11-30: 3.6M2023-12-15: 3.9M2023-12-29: 3.2M2024-01-12: 2.9M2024-01-31: 3.8M2024-02-15: 7.1M2024-02-29: 8.3M2024-03-15: 8.5M2024-03-28: 9.3M2024-04-15: 9.8M2024-04-30: 9.6M2024-05-15: 9.6M2024-05-31: 9.6M2024-06-14: 9.7M2024-06-28: 9.9M2024-07-15: 10.3M2024-07-31: 9.5M
the 31 Jul 2024 report24 earlier reportsnormal: 4.0M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 10 Jun 2026Short interest and volume change

    had 12.2M shares sold short in the 29 May 2026 report, 2.8× the same report last year.

    Same report last year: 4.4M; its normal report is 5.0M.

    See the evidence
    This period
    12.2M (the 29 May 2026 report)
    Normal report (median of 24 earlier)
    5.0M
    Typical spread (median absolute deviation)
    1.2M
    How far from its usual level
    +3.9
    Same report last year
    4.4M
    History used
    1,991 days
    2025-05-30: 4.4M2025-06-13: 4.2M2025-06-30: 3.9M2025-07-15: 3.6M2025-07-31: 3.7M2025-08-15: 4.1M2025-08-29: 4.3M2025-09-15: 4.7M2025-09-30: 4.5M2025-10-15: 4.2M2025-10-31: 4.3M2025-11-14: 5.2M2025-11-28: 5.0M2025-12-15: 5.0M2025-12-31: 8.7M2026-01-15: 9.5M2026-01-30: 9.3M2026-02-13: 9.7M2026-02-27: 10.1M2026-03-13: 10.4M2026-03-31: 10.9M2026-04-15: 11.5M2026-04-30: 12.0M2026-05-15: 12.1M2026-05-29: 12.2M
    the 29 May 2026 report24 earlier reportsnormal: 5.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  2. 28 May 2026Short interest and volume change

    had 12.1M shares sold short in the 15 May 2026 report, 2.6× the same report last year.

    Same report last year: 4.7M; its normal report is 4.9M.

    See the evidence
    This period
    12.1M (the 15 May 2026 report)
    Normal report (median of 24 earlier)
    4.9M
    Typical spread (median absolute deviation)
    844K
    How far from its usual level
    +5.8
    Same report last year
    4.7M
    History used
    1,977 days
    2025-05-15: 4.7M2025-05-30: 4.4M2025-06-13: 4.2M2025-06-30: 3.9M2025-07-15: 3.6M2025-07-31: 3.7M2025-08-15: 4.1M2025-08-29: 4.3M2025-09-15: 4.7M2025-09-30: 4.5M2025-10-15: 4.2M2025-10-31: 4.3M2025-11-14: 5.2M2025-11-28: 5.0M2025-12-15: 5.0M2025-12-31: 8.7M2026-01-15: 9.5M2026-01-30: 9.3M2026-02-13: 9.7M2026-02-27: 10.1M2026-03-13: 10.4M2026-03-31: 10.9M2026-04-15: 11.5M2026-04-30: 12.0M2026-05-15: 12.1M
    the 15 May 2026 report24 earlier reportsnormal: 4.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  3. 12 May 2026Short interest and volume change

    had 12.0M shares sold short in the 30 Apr 2026 report, 2.4× the same report last year.

    Same report last year: 5.0M; its normal report is 4.9M.

    See the evidence
    This period
    12.0M (the 30 Apr 2026 report)
    Normal report (median of 24 earlier)
    4.9M
    Typical spread (median absolute deviation)
    701K
    How far from its usual level
    +6.9
    Same report last year
    5.0M
    History used
    1,962 days
    2025-04-30: 5.0M2025-05-15: 4.7M2025-05-30: 4.4M2025-06-13: 4.2M2025-06-30: 3.9M2025-07-15: 3.6M2025-07-31: 3.7M2025-08-15: 4.1M2025-08-29: 4.3M2025-09-15: 4.7M2025-09-30: 4.5M2025-10-15: 4.2M2025-10-31: 4.3M2025-11-14: 5.2M2025-11-28: 5.0M2025-12-15: 5.0M2025-12-31: 8.7M2026-01-15: 9.5M2026-01-30: 9.3M2026-02-13: 9.7M2026-02-27: 10.1M2026-03-13: 10.4M2026-03-31: 10.9M2026-04-15: 11.5M2026-04-30: 12.0M
    the 30 Apr 2026 report24 earlier reportsnormal: 4.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  4. 25 Apr 2026Short interest and volume change

    had 11.5M shares sold short in the 15 Apr 2026 report, 2.2× the same report last year.

    Same report last year: 5.2M; its normal report is 4.9M.

    See the evidence
    This period
    11.5M (the 15 Apr 2026 report)
    Normal report (median of 24 earlier)
    4.9M
    Typical spread (median absolute deviation)
    662K
    How far from its usual level
    +6.8
    Same report last year
    5.2M
    History used
    1,947 days
    2025-04-15: 5.2M2025-04-30: 5.0M2025-05-15: 4.7M2025-05-30: 4.4M2025-06-13: 4.2M2025-06-30: 3.9M2025-07-15: 3.6M2025-07-31: 3.7M2025-08-15: 4.1M2025-08-29: 4.3M2025-09-15: 4.7M2025-09-30: 4.5M2025-10-15: 4.2M2025-10-31: 4.3M2025-11-14: 5.2M2025-11-28: 5.0M2025-12-15: 5.0M2025-12-31: 8.7M2026-01-15: 9.5M2026-01-30: 9.3M2026-02-13: 9.7M2026-02-27: 10.1M2026-03-13: 10.4M2026-03-31: 10.9M2026-04-15: 11.5M
    the 15 Apr 2026 report24 earlier reportsnormal: 4.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  5. 11 Apr 2026Short interest and volume change

    had 10.9M shares sold short in the 31 Mar 2026 report, 2.1× the same report last year.

    Same report last year: 5.1M; its normal report is 4.9M.

    See the evidence
    This period
    10.9M (the 31 Mar 2026 report)
    Normal report (median of 24 earlier)
    4.9M
    Typical spread (median absolute deviation)
    612K
    How far from its usual level
    +6.6
    Same report last year
    5.1M
    History used
    1,932 days
    2025-03-31: 5.1M2025-04-15: 5.2M2025-04-30: 5.0M2025-05-15: 4.7M2025-05-30: 4.4M2025-06-13: 4.2M2025-06-30: 3.9M2025-07-15: 3.6M2025-07-31: 3.7M2025-08-15: 4.1M2025-08-29: 4.3M2025-09-15: 4.7M2025-09-30: 4.5M2025-10-15: 4.2M2025-10-31: 4.3M2025-11-14: 5.2M2025-11-28: 5.0M2025-12-15: 5.0M2025-12-31: 8.7M2026-01-15: 9.5M2026-01-30: 9.3M2026-02-13: 9.7M2026-02-27: 10.1M2026-03-13: 10.4M2026-03-31: 10.9M
    the 31 Mar 2026 report24 earlier reportsnormal: 4.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  6. 30 Mar 2026Filings record

    Director or officer change

  7. 25 Mar 2026Short interest and volume change

    had 10.4M shares sold short in the 13 Mar 2026 report, 2.1× the same report last year.

    Same report last year: 5.0M; its normal report is 4.9M.

    See the evidence
    This period
    10.4M (the 13 Mar 2026 report)
    Normal report (median of 24 earlier)
    4.9M
    Typical spread (median absolute deviation)
    574K
    How far from its usual level
    +6.5
    Same report last year
    5.0M
    History used
    1,914 days
    2025-03-14: 5.0M2025-03-31: 5.1M2025-04-15: 5.2M2025-04-30: 5.0M2025-05-15: 4.7M2025-05-30: 4.4M2025-06-13: 4.2M2025-06-30: 3.9M2025-07-15: 3.6M2025-07-31: 3.7M2025-08-15: 4.1M2025-08-29: 4.3M2025-09-15: 4.7M2025-09-30: 4.5M2025-10-15: 4.2M2025-10-31: 4.3M2025-11-14: 5.2M2025-11-28: 5.0M2025-12-15: 5.0M2025-12-31: 8.7M2026-01-15: 9.5M2026-01-30: 9.3M2026-02-13: 9.7M2026-02-27: 10.1M2026-03-13: 10.4M
    the 13 Mar 2026 report24 earlier reportsnormal: 4.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  8. 19 Mar 2026several at once

    reported revenue of $85.1M for the quarter ended 31 Dec 2025, 85,090× the same quarter last year, while it had 12.0M shares sold short in the 30 Apr 2026 report, 2.4× the same report last year. Two unrelated kinds of activity within 119 days.

    See the evidence (10 changes)

    Short interest and volume: Short interest spike became public on 11 Feb 2026

    4D Molecular Therapeutics had 9.3M shares sold short in the 30 Jan 2026 report, 1.3× the same report last year.

    This period
    9.3M (the 30 Jan 2026 report)
    Normal report (median of 24 earlier)
    4.9M
    Typical spread (median absolute deviation)
    534K
    How far from its usual level
    +5.6
    Same report last year
    7.4M
    History used
    1,872 days
    2025-01-31: 7.4M2025-02-14: 6.2M2025-02-28: 5.2M2025-03-14: 5.0M2025-03-31: 5.1M2025-04-15: 5.2M2025-04-30: 5.0M2025-05-15: 4.7M2025-05-30: 4.4M2025-06-13: 4.2M2025-06-30: 3.9M2025-07-15: 3.6M2025-07-31: 3.7M2025-08-15: 4.1M2025-08-29: 4.3M2025-09-15: 4.7M2025-09-30: 4.5M2025-10-15: 4.2M2025-10-31: 4.3M2025-11-14: 5.2M2025-11-28: 5.0M2025-12-15: 5.0M2025-12-31: 8.7M2026-01-15: 9.5M2026-01-30: 9.3M
    the 30 Jan 2026 report24 earlier reportsnormal: 4.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 26 Feb 2026

    4D Molecular Therapeutics had 9.7M shares sold short in the 13 Feb 2026 report, 1.6× the same report last year.

    This period
    9.7M (the 13 Feb 2026 report)
    Normal report (median of 24 earlier)
    4.9M
    Typical spread (median absolute deviation)
    534K
    How far from its usual level
    +6.1
    Same report last year
    6.2M
    History used
    1,886 days
    2025-02-14: 6.2M2025-02-28: 5.2M2025-03-14: 5.0M2025-03-31: 5.1M2025-04-15: 5.2M2025-04-30: 5.0M2025-05-15: 4.7M2025-05-30: 4.4M2025-06-13: 4.2M2025-06-30: 3.9M2025-07-15: 3.6M2025-07-31: 3.7M2025-08-15: 4.1M2025-08-29: 4.3M2025-09-15: 4.7M2025-09-30: 4.5M2025-10-15: 4.2M2025-10-31: 4.3M2025-11-14: 5.2M2025-11-28: 5.0M2025-12-15: 5.0M2025-12-31: 8.7M2026-01-15: 9.5M2026-01-30: 9.3M2026-02-13: 9.7M
    the 13 Feb 2026 report24 earlier reportsnormal: 4.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 11 Mar 2026

    4D Molecular Therapeutics had 10.1M shares sold short in the 27 Feb 2026 report, 1.9× the same report last year.

    This period
    10.1M (the 27 Feb 2026 report)
    Normal report (median of 24 earlier)
    4.9M
    Typical spread (median absolute deviation)
    534K
    How far from its usual level
    +6.7
    Same report last year
    5.2M
    History used
    1,900 days
    2025-02-28: 5.2M2025-03-14: 5.0M2025-03-31: 5.1M2025-04-15: 5.2M2025-04-30: 5.0M2025-05-15: 4.7M2025-05-30: 4.4M2025-06-13: 4.2M2025-06-30: 3.9M2025-07-15: 3.6M2025-07-31: 3.7M2025-08-15: 4.1M2025-08-29: 4.3M2025-09-15: 4.7M2025-09-30: 4.5M2025-10-15: 4.2M2025-10-31: 4.3M2025-11-14: 5.2M2025-11-28: 5.0M2025-12-15: 5.0M2025-12-31: 8.7M2026-01-15: 9.5M2026-01-30: 9.3M2026-02-13: 9.7M2026-02-27: 10.1M
    the 27 Feb 2026 report24 earlier reportsnormal: 4.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Financials: Quarterly revenue change became public on 19 Mar 2026

    4D Molecular Therapeutics reported revenue of $85.1M for the quarter ended 31 Dec 2025, 85,090× the same quarter last year.

    This period
    $85.1M (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    $10K
    Typical spread (median absolute deviation)
    $8K
    How far from its usual level
    +85.1
    Same quarter last year
    $1K
    History used
    2,101 days
    2023-12-31: $02024-03-31: $28K2024-06-30: $5K2024-09-30: $3K2024-12-31: $1K2025-03-31: $14K2025-06-30: $15K2025-09-30: $90K2025-12-31: $85.1M
    the quarter ended 31 Dec 20258 earlier quartersnormal: $10K

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Short interest and volume: Short interest spike became public on 25 Mar 2026

    4D Molecular Therapeutics had 10.4M shares sold short in the 13 Mar 2026 report, 2.1× the same report last year.

    This period
    10.4M (the 13 Mar 2026 report)
    Normal report (median of 24 earlier)
    4.9M
    Typical spread (median absolute deviation)
    574K
    How far from its usual level
    +6.5
    Same report last year
    5.0M
    History used
    1,914 days
    2025-03-14: 5.0M2025-03-31: 5.1M2025-04-15: 5.2M2025-04-30: 5.0M2025-05-15: 4.7M2025-05-30: 4.4M2025-06-13: 4.2M2025-06-30: 3.9M2025-07-15: 3.6M2025-07-31: 3.7M2025-08-15: 4.1M2025-08-29: 4.3M2025-09-15: 4.7M2025-09-30: 4.5M2025-10-15: 4.2M2025-10-31: 4.3M2025-11-14: 5.2M2025-11-28: 5.0M2025-12-15: 5.0M2025-12-31: 8.7M2026-01-15: 9.5M2026-01-30: 9.3M2026-02-13: 9.7M2026-02-27: 10.1M2026-03-13: 10.4M
    the 13 Mar 2026 report24 earlier reportsnormal: 4.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 11 Apr 2026

    4D Molecular Therapeutics had 10.9M shares sold short in the 31 Mar 2026 report, 2.1× the same report last year.

    This period
    10.9M (the 31 Mar 2026 report)
    Normal report (median of 24 earlier)
    4.9M
    Typical spread (median absolute deviation)
    612K
    How far from its usual level
    +6.6
    Same report last year
    5.1M
    History used
    1,932 days
    2025-03-31: 5.1M2025-04-15: 5.2M2025-04-30: 5.0M2025-05-15: 4.7M2025-05-30: 4.4M2025-06-13: 4.2M2025-06-30: 3.9M2025-07-15: 3.6M2025-07-31: 3.7M2025-08-15: 4.1M2025-08-29: 4.3M2025-09-15: 4.7M2025-09-30: 4.5M2025-10-15: 4.2M2025-10-31: 4.3M2025-11-14: 5.2M2025-11-28: 5.0M2025-12-15: 5.0M2025-12-31: 8.7M2026-01-15: 9.5M2026-01-30: 9.3M2026-02-13: 9.7M2026-02-27: 10.1M2026-03-13: 10.4M2026-03-31: 10.9M
    the 31 Mar 2026 report24 earlier reportsnormal: 4.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 25 Apr 2026

    4D Molecular Therapeutics had 11.5M shares sold short in the 15 Apr 2026 report, 2.2× the same report last year.

    This period
    11.5M (the 15 Apr 2026 report)
    Normal report (median of 24 earlier)
    4.9M
    Typical spread (median absolute deviation)
    662K
    How far from its usual level
    +6.8
    Same report last year
    5.2M
    History used
    1,947 days
    2025-04-15: 5.2M2025-04-30: 5.0M2025-05-15: 4.7M2025-05-30: 4.4M2025-06-13: 4.2M2025-06-30: 3.9M2025-07-15: 3.6M2025-07-31: 3.7M2025-08-15: 4.1M2025-08-29: 4.3M2025-09-15: 4.7M2025-09-30: 4.5M2025-10-15: 4.2M2025-10-31: 4.3M2025-11-14: 5.2M2025-11-28: 5.0M2025-12-15: 5.0M2025-12-31: 8.7M2026-01-15: 9.5M2026-01-30: 9.3M2026-02-13: 9.7M2026-02-27: 10.1M2026-03-13: 10.4M2026-03-31: 10.9M2026-04-15: 11.5M
    the 15 Apr 2026 report24 earlier reportsnormal: 4.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 12 May 2026

    4D Molecular Therapeutics had 12.0M shares sold short in the 30 Apr 2026 report, 2.4× the same report last year.

    This period
    12.0M (the 30 Apr 2026 report)
    Normal report (median of 24 earlier)
    4.9M
    Typical spread (median absolute deviation)
    701K
    How far from its usual level
    +6.9
    Same report last year
    5.0M
    History used
    1,962 days
    2025-04-30: 5.0M2025-05-15: 4.7M2025-05-30: 4.4M2025-06-13: 4.2M2025-06-30: 3.9M2025-07-15: 3.6M2025-07-31: 3.7M2025-08-15: 4.1M2025-08-29: 4.3M2025-09-15: 4.7M2025-09-30: 4.5M2025-10-15: 4.2M2025-10-31: 4.3M2025-11-14: 5.2M2025-11-28: 5.0M2025-12-15: 5.0M2025-12-31: 8.7M2026-01-15: 9.5M2026-01-30: 9.3M2026-02-13: 9.7M2026-02-27: 10.1M2026-03-13: 10.4M2026-03-31: 10.9M2026-04-15: 11.5M2026-04-30: 12.0M
    the 30 Apr 2026 report24 earlier reportsnormal: 4.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 28 May 2026

    4D Molecular Therapeutics had 12.1M shares sold short in the 15 May 2026 report, 2.6× the same report last year.

    This period
    12.1M (the 15 May 2026 report)
    Normal report (median of 24 earlier)
    4.9M
    Typical spread (median absolute deviation)
    844K
    How far from its usual level
    +5.8
    Same report last year
    4.7M
    History used
    1,977 days
    2025-05-15: 4.7M2025-05-30: 4.4M2025-06-13: 4.2M2025-06-30: 3.9M2025-07-15: 3.6M2025-07-31: 3.7M2025-08-15: 4.1M2025-08-29: 4.3M2025-09-15: 4.7M2025-09-30: 4.5M2025-10-15: 4.2M2025-10-31: 4.3M2025-11-14: 5.2M2025-11-28: 5.0M2025-12-15: 5.0M2025-12-31: 8.7M2026-01-15: 9.5M2026-01-30: 9.3M2026-02-13: 9.7M2026-02-27: 10.1M2026-03-13: 10.4M2026-03-31: 10.9M2026-04-15: 11.5M2026-04-30: 12.0M2026-05-15: 12.1M
    the 15 May 2026 report24 earlier reportsnormal: 4.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 10 Jun 2026

    4D Molecular Therapeutics had 12.2M shares sold short in the 29 May 2026 report, 2.8× the same report last year.

    This period
    12.2M (the 29 May 2026 report)
    Normal report (median of 24 earlier)
    5.0M
    Typical spread (median absolute deviation)
    1.2M
    How far from its usual level
    +3.9
    Same report last year
    4.4M
    History used
    1,991 days
    2025-05-30: 4.4M2025-06-13: 4.2M2025-06-30: 3.9M2025-07-15: 3.6M2025-07-31: 3.7M2025-08-15: 4.1M2025-08-29: 4.3M2025-09-15: 4.7M2025-09-30: 4.5M2025-10-15: 4.2M2025-10-31: 4.3M2025-11-14: 5.2M2025-11-28: 5.0M2025-12-15: 5.0M2025-12-31: 8.7M2026-01-15: 9.5M2026-01-30: 9.3M2026-02-13: 9.7M2026-02-27: 10.1M2026-03-13: 10.4M2026-03-31: 10.9M2026-04-15: 11.5M2026-04-30: 12.0M2026-05-15: 12.1M2026-05-29: 12.2M
    the 29 May 2026 report24 earlier reportsnormal: 5.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  9. 19 Mar 2026Financials change

    reported revenue of $85.1M for the quarter ended 31 Dec 2025, 85,090× the same quarter last year.

    Same quarter last year: $1K; its normal quarter is $10K.

    See the evidence
    This period
    $85.1M (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    $10K
    Typical spread (median absolute deviation)
    $8K
    How far from its usual level
    +85.1
    Same quarter last year
    $1K
    History used
    2,101 days
    2023-12-31: $02024-03-31: $28K2024-06-30: $5K2024-09-30: $3K2024-12-31: $1K2025-03-31: $14K2025-06-30: $15K2025-09-30: $90K2025-12-31: $85.1M
    the quarter ended 31 Dec 20258 earlier quartersnormal: $10K

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  10. 11 Mar 2026Short interest and volume change

    had 10.1M shares sold short in the 27 Feb 2026 report, 1.9× the same report last year.

    Same report last year: 5.2M; its normal report is 4.9M.

    See the evidence
    This period
    10.1M (the 27 Feb 2026 report)
    Normal report (median of 24 earlier)
    4.9M
    Typical spread (median absolute deviation)
    534K
    How far from its usual level
    +6.7
    Same report last year
    5.2M
    History used
    1,900 days
    2025-02-28: 5.2M2025-03-14: 5.0M2025-03-31: 5.1M2025-04-15: 5.2M2025-04-30: 5.0M2025-05-15: 4.7M2025-05-30: 4.4M2025-06-13: 4.2M2025-06-30: 3.9M2025-07-15: 3.6M2025-07-31: 3.7M2025-08-15: 4.1M2025-08-29: 4.3M2025-09-15: 4.7M2025-09-30: 4.5M2025-10-15: 4.2M2025-10-31: 4.3M2025-11-14: 5.2M2025-11-28: 5.0M2025-12-15: 5.0M2025-12-31: 8.7M2026-01-15: 9.5M2026-01-30: 9.3M2026-02-13: 9.7M2026-02-27: 10.1M
    the 27 Feb 2026 report24 earlier reportsnormal: 4.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  11. 26 Feb 2026Short interest and volume change

    had 9.7M shares sold short in the 13 Feb 2026 report, 1.6× the same report last year.

    Same report last year: 6.2M; its normal report is 4.9M.

    See the evidence
    This period
    9.7M (the 13 Feb 2026 report)
    Normal report (median of 24 earlier)
    4.9M
    Typical spread (median absolute deviation)
    534K
    How far from its usual level
    +6.1
    Same report last year
    6.2M
    History used
    1,886 days
    2025-02-14: 6.2M2025-02-28: 5.2M2025-03-14: 5.0M2025-03-31: 5.1M2025-04-15: 5.2M2025-04-30: 5.0M2025-05-15: 4.7M2025-05-30: 4.4M2025-06-13: 4.2M2025-06-30: 3.9M2025-07-15: 3.6M2025-07-31: 3.7M2025-08-15: 4.1M2025-08-29: 4.3M2025-09-15: 4.7M2025-09-30: 4.5M2025-10-15: 4.2M2025-10-31: 4.3M2025-11-14: 5.2M2025-11-28: 5.0M2025-12-15: 5.0M2025-12-31: 8.7M2026-01-15: 9.5M2026-01-30: 9.3M2026-02-13: 9.7M
    the 13 Feb 2026 report24 earlier reportsnormal: 4.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  12. 11 Feb 2026Short interest and volume change

    had 9.3M shares sold short in the 30 Jan 2026 report, 1.3× the same report last year.

    Same report last year: 7.4M; its normal report is 4.9M.

    See the evidence
    This period
    9.3M (the 30 Jan 2026 report)
    Normal report (median of 24 earlier)
    4.9M
    Typical spread (median absolute deviation)
    534K
    How far from its usual level
    +5.6
    Same report last year
    7.4M
    History used
    1,872 days
    2025-01-31: 7.4M2025-02-14: 6.2M2025-02-28: 5.2M2025-03-14: 5.0M2025-03-31: 5.1M2025-04-15: 5.2M2025-04-30: 5.0M2025-05-15: 4.7M2025-05-30: 4.4M2025-06-13: 4.2M2025-06-30: 3.9M2025-07-15: 3.6M2025-07-31: 3.7M2025-08-15: 4.1M2025-08-29: 4.3M2025-09-15: 4.7M2025-09-30: 4.5M2025-10-15: 4.2M2025-10-31: 4.3M2025-11-14: 5.2M2025-11-28: 5.0M2025-12-15: 5.0M2025-12-31: 8.7M2026-01-15: 9.5M2026-01-30: 9.3M
    the 30 Jan 2026 report24 earlier reportsnormal: 4.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  13. 28 Jan 2026Short interest and volume change

    had 9.5M shares sold short in the 15 Jan 2026 report, 1.2× the same report last year.

    Same report last year: 7.7M; its normal report is 4.9M.

    See the evidence
    This period
    9.5M (the 15 Jan 2026 report)
    Normal report (median of 24 earlier)
    4.9M
    Typical spread (median absolute deviation)
    534K
    How far from its usual level
    +5.8
    Same report last year
    7.7M
    History used
    1,857 days
    2025-01-15: 7.7M2025-01-31: 7.4M2025-02-14: 6.2M2025-02-28: 5.2M2025-03-14: 5.0M2025-03-31: 5.1M2025-04-15: 5.2M2025-04-30: 5.0M2025-05-15: 4.7M2025-05-30: 4.4M2025-06-13: 4.2M2025-06-30: 3.9M2025-07-15: 3.6M2025-07-31: 3.7M2025-08-15: 4.1M2025-08-29: 4.3M2025-09-15: 4.7M2025-09-30: 4.5M2025-10-15: 4.2M2025-10-31: 4.3M2025-11-14: 5.2M2025-11-28: 5.0M2025-12-15: 5.0M2025-12-31: 8.7M2026-01-15: 9.5M
    the 15 Jan 2026 report24 earlier reportsnormal: 4.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  14. 13 Jan 2026Short interest and volume change

    had 8.7M shares sold short in the 31 Dec 2025 report, 1.1× the same report last year.

    Same report last year: 8.0M; its normal report is 4.9M.

    See the evidence
    This period
    8.7M (the 31 Dec 2025 report)
    Normal report (median of 24 earlier)
    4.9M
    Typical spread (median absolute deviation)
    534K
    How far from its usual level
    +4.8
    Same report last year
    8.0M
    History used
    1,842 days
    2024-12-31: 8.0M2025-01-15: 7.7M2025-01-31: 7.4M2025-02-14: 6.2M2025-02-28: 5.2M2025-03-14: 5.0M2025-03-31: 5.1M2025-04-15: 5.2M2025-04-30: 5.0M2025-05-15: 4.7M2025-05-30: 4.4M2025-06-13: 4.2M2025-06-30: 3.9M2025-07-15: 3.6M2025-07-31: 3.7M2025-08-15: 4.1M2025-08-29: 4.3M2025-09-15: 4.7M2025-09-30: 4.5M2025-10-15: 4.2M2025-10-31: 4.3M2025-11-14: 5.2M2025-11-28: 5.0M2025-12-15: 5.0M2025-12-31: 8.7M
    the 31 Dec 2025 report24 earlier reportsnormal: 4.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  15. 7 Jan 2026Filings record

    Director or officer change

  16. 17 Nov 2025Filings record

    Director or officer change

  17. 2 Oct 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  18. 2 Oct 2025Filings record

    Director or officer change

  19. 2 Jul 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  20. 2 Jul 2025Filings record

    Director or officer change

  21. 10 Aug 2024Short interest and volume change

    had 9.5M shares sold short in the 31 Jul 2024 report, 3.1× the same report last year.

    Same report last year: 3.1M; its normal report is 4.0M.

    See the evidence
    This period
    9.5M (the 31 Jul 2024 report)
    Normal report (median of 24 earlier)
    4.0M
    Typical spread (median absolute deviation)
    1.0M
    How far from its usual level
    +3.6
    Same report last year
    3.1M
    History used
    1,324 days
    2023-07-31: 3.1M2023-08-15: 3.6M2023-08-31: 3.6M2023-09-15: 3.7M2023-09-29: 3.9M2023-10-13: 4.1M2023-10-31: 3.5M2023-11-15: 3.8M2023-11-30: 3.6M2023-12-15: 3.9M2023-12-29: 3.2M2024-01-12: 2.9M2024-01-31: 3.8M2024-02-15: 7.1M2024-02-29: 8.3M2024-03-15: 8.5M2024-03-28: 9.3M2024-04-15: 9.8M2024-04-30: 9.6M2024-05-15: 9.6M2024-05-31: 9.6M2024-06-14: 9.7M2024-06-28: 9.9M2024-07-15: 10.3M2024-07-31: 9.5M
    the 31 Jul 2024 report24 earlier reportsnormal: 4.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  22. 25 Jul 2024Short interest and volume change

    had 10.3M shares sold short in the 15 Jul 2024 report, 3.3× the same report last year.

    Same report last year: 3.1M; its normal report is 3.9M.

    See the evidence
    This period
    10.3M (the 15 Jul 2024 report)
    Normal report (median of 24 earlier)
    3.9M
    Typical spread (median absolute deviation)
    836K
    How far from its usual level
    +5.2
    Same report last year
    3.1M
    History used
    1,308 days
    2023-07-14: 3.1M2023-07-31: 3.1M2023-08-15: 3.6M2023-08-31: 3.6M2023-09-15: 3.7M2023-09-29: 3.9M2023-10-13: 4.1M2023-10-31: 3.5M2023-11-15: 3.8M2023-11-30: 3.6M2023-12-15: 3.9M2023-12-29: 3.2M2024-01-12: 2.9M2024-01-31: 3.8M2024-02-15: 7.1M2024-02-29: 8.3M2024-03-15: 8.5M2024-03-28: 9.3M2024-04-15: 9.8M2024-04-30: 9.6M2024-05-15: 9.6M2024-05-31: 9.6M2024-06-14: 9.7M2024-06-28: 9.9M2024-07-15: 10.3M
    the 15 Jul 2024 report24 earlier reportsnormal: 3.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  23. 11 Jul 2024Short interest and volume change

    had 9.9M shares sold short in the 28 Jun 2024 report, 2.8× the same report last year.

    Same report last year: 3.5M; its normal report is 3.9M.

    See the evidence
    This period
    9.9M (the 28 Jun 2024 report)
    Normal report (median of 24 earlier)
    3.9M
    Typical spread (median absolute deviation)
    718K
    How far from its usual level
    +5.6
    Same report last year
    3.5M
    History used
    1,291 days
    2023-06-30: 3.5M2023-07-14: 3.1M2023-07-31: 3.1M2023-08-15: 3.6M2023-08-31: 3.6M2023-09-15: 3.7M2023-09-29: 3.9M2023-10-13: 4.1M2023-10-31: 3.5M2023-11-15: 3.8M2023-11-30: 3.6M2023-12-15: 3.9M2023-12-29: 3.2M2024-01-12: 2.9M2024-01-31: 3.8M2024-02-15: 7.1M2024-02-29: 8.3M2024-03-15: 8.5M2024-03-28: 9.3M2024-04-15: 9.8M2024-04-30: 9.6M2024-05-15: 9.6M2024-05-31: 9.6M2024-06-14: 9.7M2024-06-28: 9.9M
    the 28 Jun 2024 report24 earlier reportsnormal: 3.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  24. 27 Jun 2024Short interest and volume change

    had 9.7M shares sold short in the 14 Jun 2024 report, 2.8× the same report last year.

    Same report last year: 3.4M; its normal report is 3.8M.

    See the evidence
    This period
    9.7M (the 14 Jun 2024 report)
    Normal report (median of 24 earlier)
    3.8M
    Typical spread (median absolute deviation)
    482K
    How far from its usual level
    +8.3
    Same report last year
    3.4M
    History used
    1,277 days
    2023-06-15: 3.4M2023-06-30: 3.5M2023-07-14: 3.1M2023-07-31: 3.1M2023-08-15: 3.6M2023-08-31: 3.6M2023-09-15: 3.7M2023-09-29: 3.9M2023-10-13: 4.1M2023-10-31: 3.5M2023-11-15: 3.8M2023-11-30: 3.6M2023-12-15: 3.9M2023-12-29: 3.2M2024-01-12: 2.9M2024-01-31: 3.8M2024-02-15: 7.1M2024-02-29: 8.3M2024-03-15: 8.5M2024-03-28: 9.3M2024-04-15: 9.8M2024-04-30: 9.6M2024-05-15: 9.6M2024-05-31: 9.6M2024-06-14: 9.7M
    the 14 Jun 2024 report24 earlier reportsnormal: 3.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  25. 12 Jun 2024Short interest and volume change

    had 9.6M shares sold short in the 31 May 2024 report, 3.1× the same report last year.

    Same report last year: 3.1M; its normal report is 3.7M.

    See the evidence
    This period
    9.6M (the 31 May 2024 report)
    Normal report (median of 24 earlier)
    3.7M
    Typical spread (median absolute deviation)
    440K
    How far from its usual level
    +9.0
    Same report last year
    3.1M
    History used
    1,263 days
    2023-05-31: 3.1M2023-06-15: 3.4M2023-06-30: 3.5M2023-07-14: 3.1M2023-07-31: 3.1M2023-08-15: 3.6M2023-08-31: 3.6M2023-09-15: 3.7M2023-09-29: 3.9M2023-10-13: 4.1M2023-10-31: 3.5M2023-11-15: 3.8M2023-11-30: 3.6M2023-12-15: 3.9M2023-12-29: 3.2M2024-01-12: 2.9M2024-01-31: 3.8M2024-02-15: 7.1M2024-02-29: 8.3M2024-03-15: 8.5M2024-03-28: 9.3M2024-04-15: 9.8M2024-04-30: 9.6M2024-05-15: 9.6M2024-05-31: 9.6M
    the 31 May 2024 report24 earlier reportsnormal: 3.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  26. 25 May 2024Short interest and volume change

    had 9.6M shares sold short in the 15 May 2024 report, 3.3× the same report last year.

    Same report last year: 3.0M; its normal report is 3.6M.

    See the evidence
    This period
    9.6M (the 15 May 2024 report)
    Normal report (median of 24 earlier)
    3.6M
    Typical spread (median absolute deviation)
    440K
    How far from its usual level
    +9.2
    Same report last year
    3.0M
    History used
    1,247 days
    2023-05-15: 3.0M2023-05-31: 3.1M2023-06-15: 3.4M2023-06-30: 3.5M2023-07-14: 3.1M2023-07-31: 3.1M2023-08-15: 3.6M2023-08-31: 3.6M2023-09-15: 3.7M2023-09-29: 3.9M2023-10-13: 4.1M2023-10-31: 3.5M2023-11-15: 3.8M2023-11-30: 3.6M2023-12-15: 3.9M2023-12-29: 3.2M2024-01-12: 2.9M2024-01-31: 3.8M2024-02-15: 7.1M2024-02-29: 8.3M2024-03-15: 8.5M2024-03-28: 9.3M2024-04-15: 9.8M2024-04-30: 9.6M2024-05-15: 9.6M
    the 15 May 2024 report24 earlier reportsnormal: 3.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  27. 21 May 2024several at once

    saw 51 13F filers open a new position in the quarter ended 31 Mar 2024, 3.9× the same quarter last year, while it had 9.7M shares sold short in the 14 Jun 2024 report, 2.8× the same report last year. Two unrelated kinds of activity within 105 days.

    See the evidence (9 changes)

    Short interest and volume: Short interest spike became public on 25 Apr 2024

    4D Molecular Therapeutics had 9.8M shares sold short in the 15 Apr 2024 report, 3.1× the same report last year.

    This period
    9.8M (the 15 Apr 2024 report)
    Normal report (median of 24 earlier)
    3.6M
    Typical spread (median absolute deviation)
    385K
    How far from its usual level
    +11.0
    Same report last year
    3.2M
    History used
    1,217 days
    2023-04-14: 3.2M2023-04-28: 2.8M2023-05-15: 3.0M2023-05-31: 3.1M2023-06-15: 3.4M2023-06-30: 3.5M2023-07-14: 3.1M2023-07-31: 3.1M2023-08-15: 3.6M2023-08-31: 3.6M2023-09-15: 3.7M2023-09-29: 3.9M2023-10-13: 4.1M2023-10-31: 3.5M2023-11-15: 3.8M2023-11-30: 3.6M2023-12-15: 3.9M2023-12-29: 3.2M2024-01-12: 2.9M2024-01-31: 3.8M2024-02-15: 7.1M2024-02-29: 8.3M2024-03-15: 8.5M2024-03-28: 9.3M2024-04-15: 9.8M
    the 15 Apr 2024 report24 earlier reportsnormal: 3.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 10 May 2024

    4D Molecular Therapeutics had 9.6M shares sold short in the 30 Apr 2024 report, 3.4× the same report last year.

    This period
    9.6M (the 30 Apr 2024 report)
    Normal report (median of 24 earlier)
    3.6M
    Typical spread (median absolute deviation)
    418K
    How far from its usual level
    +9.7
    Same report last year
    2.8M
    History used
    1,232 days
    2023-04-28: 2.8M2023-05-15: 3.0M2023-05-31: 3.1M2023-06-15: 3.4M2023-06-30: 3.5M2023-07-14: 3.1M2023-07-31: 3.1M2023-08-15: 3.6M2023-08-31: 3.6M2023-09-15: 3.7M2023-09-29: 3.9M2023-10-13: 4.1M2023-10-31: 3.5M2023-11-15: 3.8M2023-11-30: 3.6M2023-12-15: 3.9M2023-12-29: 3.2M2024-01-12: 2.9M2024-01-31: 3.8M2024-02-15: 7.1M2024-02-29: 8.3M2024-03-15: 8.5M2024-03-28: 9.3M2024-04-15: 9.8M2024-04-30: 9.6M
    the 30 Apr 2024 report24 earlier reportsnormal: 3.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Institutional holdings: Many funds opening a new position became public on 15 May 2024

    4D Molecular Therapeutics saw 51 13F filers open a new position in the quarter ended 31 Mar 2024, 3.9× the same quarter last year.

    This period
    51 (the quarter ended 31 Mar 2024)
    Normal quarter (median of 8 earlier)
    17.5
    Typical spread (median absolute deviation)
    5
    How far from its usual level
    +4.5
    Same quarter last year
    13
    History used
    1,186 days
    2022-03-31: 82022-06-30: 232022-09-30: 122022-12-31: 232023-03-31: 132023-06-30: 202023-09-30: 182023-12-31: 172024-03-31: 51
    the quarter ended 31 Mar 20248 earlier quartersnormal: 17.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Short interest and volume: Short interest spike became public on 25 May 2024

    4D Molecular Therapeutics had 9.6M shares sold short in the 15 May 2024 report, 3.3× the same report last year.

    This period
    9.6M (the 15 May 2024 report)
    Normal report (median of 24 earlier)
    3.6M
    Typical spread (median absolute deviation)
    440K
    How far from its usual level
    +9.2
    Same report last year
    3.0M
    History used
    1,247 days
    2023-05-15: 3.0M2023-05-31: 3.1M2023-06-15: 3.4M2023-06-30: 3.5M2023-07-14: 3.1M2023-07-31: 3.1M2023-08-15: 3.6M2023-08-31: 3.6M2023-09-15: 3.7M2023-09-29: 3.9M2023-10-13: 4.1M2023-10-31: 3.5M2023-11-15: 3.8M2023-11-30: 3.6M2023-12-15: 3.9M2023-12-29: 3.2M2024-01-12: 2.9M2024-01-31: 3.8M2024-02-15: 7.1M2024-02-29: 8.3M2024-03-15: 8.5M2024-03-28: 9.3M2024-04-15: 9.8M2024-04-30: 9.6M2024-05-15: 9.6M
    the 15 May 2024 report24 earlier reportsnormal: 3.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 12 Jun 2024

    4D Molecular Therapeutics had 9.6M shares sold short in the 31 May 2024 report, 3.1× the same report last year.

    This period
    9.6M (the 31 May 2024 report)
    Normal report (median of 24 earlier)
    3.7M
    Typical spread (median absolute deviation)
    440K
    How far from its usual level
    +9.0
    Same report last year
    3.1M
    History used
    1,263 days
    2023-05-31: 3.1M2023-06-15: 3.4M2023-06-30: 3.5M2023-07-14: 3.1M2023-07-31: 3.1M2023-08-15: 3.6M2023-08-31: 3.6M2023-09-15: 3.7M2023-09-29: 3.9M2023-10-13: 4.1M2023-10-31: 3.5M2023-11-15: 3.8M2023-11-30: 3.6M2023-12-15: 3.9M2023-12-29: 3.2M2024-01-12: 2.9M2024-01-31: 3.8M2024-02-15: 7.1M2024-02-29: 8.3M2024-03-15: 8.5M2024-03-28: 9.3M2024-04-15: 9.8M2024-04-30: 9.6M2024-05-15: 9.6M2024-05-31: 9.6M
    the 31 May 2024 report24 earlier reportsnormal: 3.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 27 Jun 2024

    4D Molecular Therapeutics had 9.7M shares sold short in the 14 Jun 2024 report, 2.8× the same report last year.

    This period
    9.7M (the 14 Jun 2024 report)
    Normal report (median of 24 earlier)
    3.8M
    Typical spread (median absolute deviation)
    482K
    How far from its usual level
    +8.3
    Same report last year
    3.4M
    History used
    1,277 days
    2023-06-15: 3.4M2023-06-30: 3.5M2023-07-14: 3.1M2023-07-31: 3.1M2023-08-15: 3.6M2023-08-31: 3.6M2023-09-15: 3.7M2023-09-29: 3.9M2023-10-13: 4.1M2023-10-31: 3.5M2023-11-15: 3.8M2023-11-30: 3.6M2023-12-15: 3.9M2023-12-29: 3.2M2024-01-12: 2.9M2024-01-31: 3.8M2024-02-15: 7.1M2024-02-29: 8.3M2024-03-15: 8.5M2024-03-28: 9.3M2024-04-15: 9.8M2024-04-30: 9.6M2024-05-15: 9.6M2024-05-31: 9.6M2024-06-14: 9.7M
    the 14 Jun 2024 report24 earlier reportsnormal: 3.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 11 Jul 2024

    4D Molecular Therapeutics had 9.9M shares sold short in the 28 Jun 2024 report, 2.8× the same report last year.

    This period
    9.9M (the 28 Jun 2024 report)
    Normal report (median of 24 earlier)
    3.9M
    Typical spread (median absolute deviation)
    718K
    How far from its usual level
    +5.6
    Same report last year
    3.5M
    History used
    1,291 days
    2023-06-30: 3.5M2023-07-14: 3.1M2023-07-31: 3.1M2023-08-15: 3.6M2023-08-31: 3.6M2023-09-15: 3.7M2023-09-29: 3.9M2023-10-13: 4.1M2023-10-31: 3.5M2023-11-15: 3.8M2023-11-30: 3.6M2023-12-15: 3.9M2023-12-29: 3.2M2024-01-12: 2.9M2024-01-31: 3.8M2024-02-15: 7.1M2024-02-29: 8.3M2024-03-15: 8.5M2024-03-28: 9.3M2024-04-15: 9.8M2024-04-30: 9.6M2024-05-15: 9.6M2024-05-31: 9.6M2024-06-14: 9.7M2024-06-28: 9.9M
    the 28 Jun 2024 report24 earlier reportsnormal: 3.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 25 Jul 2024

    4D Molecular Therapeutics had 10.3M shares sold short in the 15 Jul 2024 report, 3.3× the same report last year.

    This period
    10.3M (the 15 Jul 2024 report)
    Normal report (median of 24 earlier)
    3.9M
    Typical spread (median absolute deviation)
    836K
    How far from its usual level
    +5.2
    Same report last year
    3.1M
    History used
    1,308 days
    2023-07-14: 3.1M2023-07-31: 3.1M2023-08-15: 3.6M2023-08-31: 3.6M2023-09-15: 3.7M2023-09-29: 3.9M2023-10-13: 4.1M2023-10-31: 3.5M2023-11-15: 3.8M2023-11-30: 3.6M2023-12-15: 3.9M2023-12-29: 3.2M2024-01-12: 2.9M2024-01-31: 3.8M2024-02-15: 7.1M2024-02-29: 8.3M2024-03-15: 8.5M2024-03-28: 9.3M2024-04-15: 9.8M2024-04-30: 9.6M2024-05-15: 9.6M2024-05-31: 9.6M2024-06-14: 9.7M2024-06-28: 9.9M2024-07-15: 10.3M
    the 15 Jul 2024 report24 earlier reportsnormal: 3.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 10 Aug 2024

    4D Molecular Therapeutics had 9.5M shares sold short in the 31 Jul 2024 report, 3.1× the same report last year.

    This period
    9.5M (the 31 Jul 2024 report)
    Normal report (median of 24 earlier)
    4.0M
    Typical spread (median absolute deviation)
    1.0M
    How far from its usual level
    +3.6
    Same report last year
    3.1M
    History used
    1,324 days
    2023-07-31: 3.1M2023-08-15: 3.6M2023-08-31: 3.6M2023-09-15: 3.7M2023-09-29: 3.9M2023-10-13: 4.1M2023-10-31: 3.5M2023-11-15: 3.8M2023-11-30: 3.6M2023-12-15: 3.9M2023-12-29: 3.2M2024-01-12: 2.9M2024-01-31: 3.8M2024-02-15: 7.1M2024-02-29: 8.3M2024-03-15: 8.5M2024-03-28: 9.3M2024-04-15: 9.8M2024-04-30: 9.6M2024-05-15: 9.6M2024-05-31: 9.6M2024-06-14: 9.7M2024-06-28: 9.9M2024-07-15: 10.3M2024-07-31: 9.5M
    the 31 Jul 2024 report24 earlier reportsnormal: 4.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  28. 15 May 2024Institutional holdings change

    saw 51 13F filers open a new position in the quarter ended 31 Mar 2024, 3.9× the same quarter last year.

    Same quarter last year: 13; its normal quarter is 17.5.

    See the evidence
    This period
    51 (the quarter ended 31 Mar 2024)
    Normal quarter (median of 8 earlier)
    17.5
    Typical spread (median absolute deviation)
    5
    How far from its usual level
    +4.5
    Same quarter last year
    13
    History used
    1,186 days
    2022-03-31: 82022-06-30: 232022-09-30: 122022-12-31: 232023-03-31: 132023-06-30: 202023-09-30: 182023-12-31: 172024-03-31: 51
    the quarter ended 31 Mar 20248 earlier quartersnormal: 17.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  29. 10 May 2024Short interest and volume change

    had 9.6M shares sold short in the 30 Apr 2024 report, 3.4× the same report last year.

    Same report last year: 2.8M; its normal report is 3.6M.

    See the evidence
    This period
    9.6M (the 30 Apr 2024 report)
    Normal report (median of 24 earlier)
    3.6M
    Typical spread (median absolute deviation)
    418K
    How far from its usual level
    +9.7
    Same report last year
    2.8M
    History used
    1,232 days
    2023-04-28: 2.8M2023-05-15: 3.0M2023-05-31: 3.1M2023-06-15: 3.4M2023-06-30: 3.5M2023-07-14: 3.1M2023-07-31: 3.1M2023-08-15: 3.6M2023-08-31: 3.6M2023-09-15: 3.7M2023-09-29: 3.9M2023-10-13: 4.1M2023-10-31: 3.5M2023-11-15: 3.8M2023-11-30: 3.6M2023-12-15: 3.9M2023-12-29: 3.2M2024-01-12: 2.9M2024-01-31: 3.8M2024-02-15: 7.1M2024-02-29: 8.3M2024-03-15: 8.5M2024-03-28: 9.3M2024-04-15: 9.8M2024-04-30: 9.6M
    the 30 Apr 2024 report24 earlier reportsnormal: 3.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  30. 25 Apr 2024Short interest and volume change

    had 9.8M shares sold short in the 15 Apr 2024 report, 3.1× the same report last year.

    Same report last year: 3.2M; its normal report is 3.6M.

    See the evidence
    This period
    9.8M (the 15 Apr 2024 report)
    Normal report (median of 24 earlier)
    3.6M
    Typical spread (median absolute deviation)
    385K
    How far from its usual level
    +11.0
    Same report last year
    3.2M
    History used
    1,217 days
    2023-04-14: 3.2M2023-04-28: 2.8M2023-05-15: 3.0M2023-05-31: 3.1M2023-06-15: 3.4M2023-06-30: 3.5M2023-07-14: 3.1M2023-07-31: 3.1M2023-08-15: 3.6M2023-08-31: 3.6M2023-09-15: 3.7M2023-09-29: 3.9M2023-10-13: 4.1M2023-10-31: 3.5M2023-11-15: 3.8M2023-11-30: 3.6M2023-12-15: 3.9M2023-12-29: 3.2M2024-01-12: 2.9M2024-01-31: 3.8M2024-02-15: 7.1M2024-02-29: 8.3M2024-03-15: 8.5M2024-03-28: 9.3M2024-04-15: 9.8M
    the 15 Apr 2024 report24 earlier reportsnormal: 3.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  31. 10 Apr 2024Short interest and volume change

    had 9.3M shares sold short in the 28 Mar 2024 report, 3.0× the same report last year.

    Same report last year: 3.1M; its normal report is 3.5M.

    See the evidence
    This period
    9.3M (the 28 Mar 2024 report)
    Normal report (median of 24 earlier)
    3.5M
    Typical spread (median absolute deviation)
    392K
    How far from its usual level
    +9.9
    Same report last year
    3.1M
    History used
    1,199 days
    2023-03-31: 3.1M2023-04-14: 3.2M2023-04-28: 2.8M2023-05-15: 3.0M2023-05-31: 3.1M2023-06-15: 3.4M2023-06-30: 3.5M2023-07-14: 3.1M2023-07-31: 3.1M2023-08-15: 3.6M2023-08-31: 3.6M2023-09-15: 3.7M2023-09-29: 3.9M2023-10-13: 4.1M2023-10-31: 3.5M2023-11-15: 3.8M2023-11-30: 3.6M2023-12-15: 3.9M2023-12-29: 3.2M2024-01-12: 2.9M2024-01-31: 3.8M2024-02-15: 7.1M2024-02-29: 8.3M2024-03-15: 8.5M2024-03-28: 9.3M
    the 28 Mar 2024 report24 earlier reportsnormal: 3.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  32. 27 Mar 2024Short interest and volume change

    had 8.5M shares sold short in the 15 Mar 2024 report, 3.3× the same report last year.

    Same report last year: 2.6M; its normal report is 3.5M.

    See the evidence
    This period
    8.5M (the 15 Mar 2024 report)
    Normal report (median of 24 earlier)
    3.5M
    Typical spread (median absolute deviation)
    396K
    How far from its usual level
    +8.5
    Same report last year
    2.6M
    History used
    1,186 days
    2023-03-15: 2.6M2023-03-31: 3.1M2023-04-14: 3.2M2023-04-28: 2.8M2023-05-15: 3.0M2023-05-31: 3.1M2023-06-15: 3.4M2023-06-30: 3.5M2023-07-14: 3.1M2023-07-31: 3.1M2023-08-15: 3.6M2023-08-31: 3.6M2023-09-15: 3.7M2023-09-29: 3.9M2023-10-13: 4.1M2023-10-31: 3.5M2023-11-15: 3.8M2023-11-30: 3.6M2023-12-15: 3.9M2023-12-29: 3.2M2024-01-12: 2.9M2024-01-31: 3.8M2024-02-15: 7.1M2024-02-29: 8.3M2024-03-15: 8.5M
    the 15 Mar 2024 report24 earlier reportsnormal: 3.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  33. 12 Mar 2024Short interest and volume change

    had 8.3M shares sold short in the 29 Feb 2024 report, 4.0× the same report last year.

    Same report last year: 2.1M; its normal report is 3.5M.

    See the evidence
    This period
    8.3M (the 29 Feb 2024 report)
    Normal report (median of 24 earlier)
    3.5M
    Typical spread (median absolute deviation)
    355K
    How far from its usual level
    +9.3
    Same report last year
    2.1M
    History used
    1,171 days
    2023-02-28: 2.1M2023-03-15: 2.6M2023-03-31: 3.1M2023-04-14: 3.2M2023-04-28: 2.8M2023-05-15: 3.0M2023-05-31: 3.1M2023-06-15: 3.4M2023-06-30: 3.5M2023-07-14: 3.1M2023-07-31: 3.1M2023-08-15: 3.6M2023-08-31: 3.6M2023-09-15: 3.7M2023-09-29: 3.9M2023-10-13: 4.1M2023-10-31: 3.5M2023-11-15: 3.8M2023-11-30: 3.6M2023-12-15: 3.9M2023-12-29: 3.2M2024-01-12: 2.9M2024-01-31: 3.8M2024-02-15: 7.1M2024-02-29: 8.3M
    the 29 Feb 2024 report24 earlier reportsnormal: 3.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  34. 28 Feb 2024Short interest and volume change

    had 7.1M shares sold short in the 15 Feb 2024 report, 3.2× the same report last year.

    Same report last year: 2.2M; its normal report is 3.3M.

    See the evidence
    This period
    7.1M (the 15 Feb 2024 report)
    Normal report (median of 24 earlier)
    3.3M
    Typical spread (median absolute deviation)
    316K
    How far from its usual level
    +8.0
    Same report last year
    2.2M
    History used
    1,157 days
    2023-02-15: 2.2M2023-02-28: 2.1M2023-03-15: 2.6M2023-03-31: 3.1M2023-04-14: 3.2M2023-04-28: 2.8M2023-05-15: 3.0M2023-05-31: 3.1M2023-06-15: 3.4M2023-06-30: 3.5M2023-07-14: 3.1M2023-07-31: 3.1M2023-08-15: 3.6M2023-08-31: 3.6M2023-09-15: 3.7M2023-09-29: 3.9M2023-10-13: 4.1M2023-10-31: 3.5M2023-11-15: 3.8M2023-11-30: 3.6M2023-12-15: 3.9M2023-12-29: 3.2M2024-01-12: 2.9M2024-01-31: 3.8M2024-02-15: 7.1M
    the 15 Feb 2024 report24 earlier reportsnormal: 3.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  35. 4 Jan 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  36. 4 Jan 2024Filings record

    Director or officer change

  37. 14 Nov 2023Financials change

    reported revenue of $20.2M for the quarter ended 30 Sep 2023, 40× the same quarter last year.

    Same quarter last year: $500K; its normal quarter is $860K.

    See the evidence
    This period
    $20.2M (the quarter ended 30 Sep 2023)
    Normal quarter (median of 8 earlier)
    $860K
    Typical spread (median absolute deviation)
    $534K
    How far from its usual level
    +19.3
    Same quarter last year
    $500K
    History used
    1,278 days
    2021-06-30: $14.6M2021-09-30: $1.4M2022-03-31: $1.2M2022-06-30: $162K2022-09-30: $500K2022-12-31: $1.2M2023-03-31: $298K2023-06-30: $239K2023-09-30: $20.2M
    the quarter ended 30 Sep 20238 earlier quartersnormal: $860K

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  38. 13 Sep 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  39. 13 Sep 2023Filings record

    Director or officer change (dated 12 Sep 2023)

  40. 12 May 2023Insiders record

    Shabet Rose Sharon (ten percent owner) and 7 other(s) bought 850,000 shares of FDMT ($13.6M) (dated 11 May 2023)

Showing the newest 40 of 63 entries; narrow the window or the kind of data to see older ones.

Not listed: 128 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001650648
Ticker
FDMT
Domain
4dmoleculartherapeutics.com
Employer name
4D Molecular Therapeutics, Inc. (1 unverified)
Hq location
CA|EMERYVILLE|94608 (1 unverified)
Name
4D Molecular Therapeutics, Inc.
Wikidata
Q124433826
  • DOL H-1B labor condition applications and PERM certifications47 data points1 Mar 2021 to 12 May 2025
  • SEC Form 13F institutional holdings216 data points31 Dec 2020 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)90 records11 Sep 2018 to 12 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)420 data points31 Dec 2018 to 30 Sep 2026
  • SEC Form 4 insider transactions60 records, 220 data points17 Dec 2020 to 20 Oct 2026
  • FINRA short interest (twice monthly)422 data points15 Dec 2020 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)2986 data points11 Dec 2020 to 20 Nov 2026